Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Clinical trial NCT04023552 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04023552
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-12
- Primary completion
- 2026-06-30
- Enrollment
- 8323
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.